Motor Neurone Disease Trial, Recruiting NCT07006571 Sponsor: University of Trieste Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT07006571
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ALS (also known as Lou Gehrig's disease), either confirmed by lab tests or based on current clinical diagnostic standards
  • You are over 18 years old
  • Your ALS symptoms first appeared no more than 24 months (2 years) ago
  • Your condition has been getting worse over the past 3 months
  • Your breathing ability is still at a certain minimum level, as measured by a standard ALS assessment tool (confirm with trial site)
  • You are either taking riluzole or edaravone (common ALS medications) at a stable dose for at least 1 month before joining, or you are not taking any ALS-specific medication
  • You have a caregiver who can help you and who has completed the required training on how to use the study device
  • You are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • You have a fixed electrical device implanted in your body, such as a pacemaker, nerve stimulator, or hearing implant, that could be affected by electrical fields
  • You have certain metal objects inside your skull (such as splinters, screws, nails, or some implants) that could interact with electrical fields
  • You have a history of epilepsy or seizures
  • You are currently pregnant, as the effects of the study treatment on an unborn baby are not yet known

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alberto Benussi, MD, University of Trieste

Phone: +39 0403994282

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Trieste
Registry
ClinicalTrials.gov
Start date
19 May 2025
Est. completion
30 April 2029

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Difference in the ALSFRS-R between groups at 16 weeks.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov